Eprotirome is a thyromimetic drug that has been investigated for the treatment of dyslipidemia. A Phase III trial in humans was discontinued after the drug was found to have negative effects on cartilage in dogs.[1][2]

References

  1. ^ Saponaro, Federica; Sestito, Simona; Runfola, Massimiliano; Rapposelli, Simona; Chiellini, Grazia (2020). "Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders". Frontiers in Medicine. 7: 331. doi:10.3389/fmed.2020.00331. ISSN 2296-858X. PMC 7363807. PMID 32733906.
  2. ^ Unnikrishnan, A. G.; Baruah, Manash; Kalra, Sanjay (December 2012). "Thyromimetics: What does the future hold?". Indian Journal of Endocrinology and Metabolism. 16 (Suppl 2): S159–S161. doi:10.4103/2230-8210.104029. ISSN 2230-8210. PMC 3603016. PMID 23565368.